Hydroquinine’s dual ability to inhibit bacterial growth and synergize with antibiotics makes it a strong adjuvant therapy candidate. Its potential to enhance existing treatments and combat resistance highlights its importance for future antimicrobial strategies. Learn more: doi.org/10.3390/ijms...

In summary, Hydroquinine in 25% DMSO was tested against multidrug-resistant Pseudomonas aeruginosa cultured on standard media. MIC and MBC assays assessed antimicrobial activity, RT-qPCR analysed ADI-related gene expression, and molecular docking revealed potential protein interactions.

Hydroquinine reduces bacterial virulence by altering RNA expression, affecting quorum sensing and motility. Transcriptomic analysis identified 97 downregulated genes, including ADI-related ones, highlighting its broad genetic impact. A transcriptome is an organism's complete set of mRNA (2).

Hydroquinine inhibits both drug-sensitive and MDR strains of P. aeruginosa at a MIC of 2.50 mg/mL. Its ability to combat resistant bacteria makes it a promising candidate for antimicrobial therapies, especially in settings with limited resources.

Hydroquinine boosts the effectiveness of ceftazidime, an antibiotic, showing partial synergy. This reduces drug dosages, offering a powerful approach against resistant infections with fewer side effects. This synergy could transform treatment strategies for MDR pathogens.

Research shows Hydroquinine significantly downregulates ADI pathway genes in MDR P. aeruginosa. Techniques like RT-qPCR and molecular docking reveal how Hydroquinine inhibits bacterial energy production and growth, essential for addressing antibiotic resistance.

The ADI pathway generates energy for bacteria under low oxygen. Hydroquinine disrupts this process by suppressing key genes (arcA, arcB, arcC, and arcD), blocking energy production. This mechanism reduces the virulence and survival of MDR P. aeruginosa, highlighting its therapeutic potential.

Hydroquinine, an organic compound, exhibits potent antimicrobial activity against MDR. Pseudomonas aeruginosa is a key hospital-acquired pathogen. It targets the Arginine Deiminase (ADI) pathway, disrupting bacterial energy production (1).